Biology, clinical characteristics, and management of adrenocortical tumors in children
- 3 March 2005
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 45 (3), 265-273
- https://doi.org/10.1002/pbc.20318
Abstract
Childhood adrenocortical tumors (ACT) are very aggressive endocrine neoplasms whose incidence is quite low. Little is known about their pathogenesis, clinical presentation, and optimal treatment. In recent years, however, new information has been derived from the International Pediatric Adrenocortical Tumor Registry (IPACTR), and new clues to its pathogenesis have emerged. To provide an overview of the available data that may apply to pediatric ACT, we reviewed the epidemiology, pathogenesis, and treatment of ACT in adults and in children. Germline TP53 mutation is almost always the predisposing factor in childhood ACT. A unique germline mutation (TP53–R337H) has been described in Southern Brazil, where the incidence of ACT is 10–15 times the general incidence. Childhood ACT typically present during the first 5 years of life and has female predominance. Hormone hyperproduction is almost universal, and most patients present with virilization. Two‐thirds of patients have resectable tumors. Surgery is the definitive treatment for ACT, and a curative complete resection should always be attempted. Cisplatin‐based chemotherapy with mitotane is indicated for unresectable or metastatic disease, although its impact on overall outcome is slight. In childhood ACT, age, tumor size, and tumor resectability are the most important prognostic indicators. Outcome is stage‐dependent; patients with small, resectable tumors have survival rates in excess of 80%, whereas the outcome for patients with unresectable disease is dismal. Patients with large, resectable tumors have an intermediate outcome. Childhood ACT are rare, but their unique epidemiology appear to implicate novel oncogenic pathways that are unique to the pediatric population. Multi‐institutional and prospective studies are necessary to further our understanding of the pathogenesis and to improve outcomes.Keywords
This publication has 75 references indexed in Scilit:
- Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor RegistryJournal of Clinical Oncology, 2004
- Adrenal Cortical Neoplasms in the Pediatric PopulationThe American Journal of Surgical Pathology, 2003
- Relative frequency and morphology of cancers in carriers of germline TP53 mutationsOncogene, 2001
- An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinomaProceedings of the National Academy of Sciences of the United States of America, 2001
- Are There Low-Penetrance TP53 Alleles? Evidence from Childhood Adrenocortical TumorsAmerican Journal of Human Genetics, 1999
- Surgical management, DNA content, and patient survival in adrenal cortical carcinomaSurgery, 1995
- Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?Life Sciences, 1995
- Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancerEuropean Journal Of Cancer, 1993
- Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane TherapyNew England Journal of Medicine, 1990
- Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapyArchives of Internal Medicine, 1975